Recombinant Anti-EWSR1/EWS antibody [EPR4648] (ab133318)


  • Product name

    Anti-EWSR1/EWS antibody [EPR4648]
    See all EWSR1/EWS primary antibodies
  • Description

    Rabbit monoclonal [EPR4648] to EWSR1/EWS
  • Host species

  • Tested applications

    Suitable for: WB, IHC-P, ICCmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human EWSR1/EWS aa 300-400. The exact sequence is proprietary.

  • Positive control

    • K562, HeLa, Jurkat and F9 cell lysates; Human colon and spleen tissues.
  • General notes



     This product was previously labelled as EWSR1


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab133318 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 90 kDa (predicted molecular weight: 68 kDa).
IHC-P 1/500 - 1/1000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC 1/500 - 1/1000.
  • Application notes
    Is unsuitable for Flow Cyt or IP.
  • Target

    • Function

      Might normally function as a repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.
    • Tissue specificity

    • Involvement in disease

      Defects in EWSR1 are a cause of Ewing sarcoma (ES) [MIM:612219]. A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors. Note=Chromosomal aberrations involving EWSR1 are found in patients with Ewing sarcoma. Translocation t(11;22)(q24;q12) with FLI1; translocation t(7;22)(p22;q12) with ETV1; translocation t(21;22)(q22;q12) with ERG; translocation t(9;22)(q22-31;q11-12) with NR4A3. Translocation t(2;21;22)(q23;q22;q12) that forms a EWSR1-FEV fusion protein with potential oncogenic activity.
      Note=A chromosomal aberration involving EWSR1 is associated with desmoplastic small round cell tumor (DSRCT). Translocation t(11;22)(p13;q12) with WT1.
      Note=A chromosomal aberration involving EWSR1 is associated with malignant melanoma of soft parts (MMSP). Translocation t(12;22)(q13;q12) with ATF-1. Malignant melanoma of soft parts, also known as soft tissue clear cell sarcoma, is a rare tumor developing in tendons and aponeuroses.
      Note=A chromosomal aberration involving EWSR1 is associated with small round cell sarcoma. Translocation t(11;22)(p36.1;q12) with PATZ1.
      Defects in EWSR1 may be a cause of angiomatoid fibrous histiocytoma (AFH) [MIM:612160]. A distinct variant of malignant fibrous histiocytoma that typically occurs in children and adolescents and is manifest by nodular subcutaneous growth. Characteristic microscopic features include lobulated sheets of histiocyte-like cells intimately associated with areas of hemorrhage and cystic pseudovascular spaces, as well as a striking cuffing of inflammatory cells, mimicking a lymph node metastasis. Note=Chromosomal aberrations involving EWSR1 are found in patients with angiomatoid fibrous histiocytoma. Translocation t(12;22)(q13;q12) with ATF1 generates a chimeric EWSR1/ATF1 protein. Translocation t(2;22)(q33;q12) with CREB1 generates a EWSR1/CREB1 fusion gene that is most common genetic abnormality in this tumor type.
      Note=EFPS arise due to chromosomal translocations in which EWSR1 is fused to a variety of cellular transcription factors. EFPS are very potent transcriptional activators dependent on the EAD and a C-terminal DNA-binding domain contributed by the fusion partner. The spectrum of malignancies associated with EFPS are thought to arise via EFP-induced transcriptional deregulation, with the tumor phenotype specified by the EWSR1 fusion partner and cell type. Transcriptional repression of the transforming growth factor beta type II receptor (TGF beta RII) is an important target of the EWS-FLI1, EWS-ERG, or EWS-ETV1 oncogene.
    • Sequence similarities

      Belongs to the RRM TET family.
      Contains 1 IQ domain.
      Contains 1 RanBP2-type zinc finger.
      Contains 1 RRM (RNA recognition motif) domain.
    • Domain

      EWS activation domain (EAD) functions as a potent activation domain in EFPS. EWSR1 binds POLR2C but not POLR2E or POLR2G, whereas the isolated EAD binds POLR2E and POLR2G but not POLR2C. Cis-linked RNA-binding domain (RBD) can strongly and specifically repress trans-activation by the EAD.
    • Post-translational

      Phosphorylated; calmodulin-binding inhibits phosphorylation of Ser-266.
      Highly methylated on arginine residues. Methylation is mediated by PRMT1 and, at lower level by PRMT8.
    • Cellular localization

      Nucleus. Cytoplasm. Cell membrane. Relocates from cytoplasm to ribosomes upon PTK2B/FAK2 activation.
    • Information by UniProt
    • Database links

    • Alternative names

      • bK984G1.4 antibody
      • bK984G1.4 Ewing sarcoma breakpoint region 1 protein antibody
      • Ewing sarcoma breakpoint region 1 antibody
      • Ewing sarcoma breakpoint region 1 protein antibody
      • Ewings sarcoma EWS Fli1 type 1 oncogene antibody
      • EWS antibody
      • EWS oncogene antibody
      • EWS RNA binding protein 1 antibody
      • EWS_HUMAN antibody
      • EWSR 1 antibody
      • Ewsr1 antibody
      • EWSR1 protein antibody
      • RNA binding protein EWS antibody
      • RNA-binding protein EWS antibody
      see all


    • All lanes : Anti-EWSR1/EWS antibody [EPR4648] (ab133318) at 1/1000 dilution

      Lane 1 : K562 cell lysate
      Lane 2 : HeLa cell lysate
      Lane 3 : Jurkat cell lysate
      Lane 4 : F9 cell lysate

      Lysates/proteins at 10 µg per lane.

      All lanes : Goat anti-Rabbit HRP at 1/2000 dilution

      Predicted band size: 68 kDa

      Secondary antibody - anti-rabbit HRP (ab6721)

    • Immunohistochemical analysis of Paraffin Embedded Human colon tissue labelling EWSR1/EWS with ab133318 at 1/500 dilution.

    • Immunohistochemical analysis of Paraffin Embedded Human spleen tissue labelling EWSR1/EWS with ab133318 at 1/500 dilution.


    This product has been referenced in:

    • Neumann M  et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134:2595-609 (2011). IHC-P ; Human . Read more (PubMed: 21856723) »
    See 1 Publication for this product

    Customer reviews and Q&As

    1-2 of 2 Abreviews or Q&A

    Western blot
    Human Cell lysate - whole cell (SK-N-MC, SK-ES-1, RD-ES, SaOS-2 and REH cells)
    Gel Running Conditions
    Reduced Denaturing (8 %)
    Loading amount
    15 µg
    SK-N-MC, SK-ES-1, RD-ES, SaOS-2 and REH cells
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

    Mr. Christian Marx

    Verified customer

    Submitted Nov 07 2013


    The main difference between ab133288 and ab133318 is the peptide sequence used as an immunogen.
    ab133288 would recognize all isoforms except isoform 6.
    ab133318 would recognize all isoforms except isoform 4.

    Read More

    For licensing inquiries, please contact

    Sign up